Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · IEX Real-Time Price · USD
46.14
+0.10 (0.22%)
At close: Jul 19, 2024, 4:00 PM
46.19
+0.05 (0.11%)
Pre-market: Jul 22, 2024, 7:15 AM EDT
Revolution Medicines Employees
Revolution Medicines had 378 employees as of December 31, 2023. The number of employees increased by 132 or 53.66% compared to the previous year.
Employees
378
Change (1Y)
132
Growth (1Y)
53.66%
Revenue / Employee
$12,079
Profits / Employee
-$1,281,143
Market Cap
7.61B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 378 | 132 | 53.66% |
Dec 31, 2022 | 246 | 58 | 30.85% |
Dec 31, 2021 | 188 | 63 | 50.40% |
Dec 31, 2020 | 125 | 30 | 31.58% |
Dec 31, 2019 | 95 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
The Ensign Group | 35,300 |
Penumbra | 4,200 |
Repligen | 1,783 |
Ionis Pharmaceuticals | 927 |
Ascendis Pharma | 879 |
Lantheus Holdings | 834 |
Blueprint Medicines | 655 |
Intra-Cellular Therapies | 610 |
RVMD News
- 6 days ago - Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter - Benzinga
- 10 days ago - Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer - GlobeNewsWire
- 13 days ago - Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024 - GlobeNewsWire
- 14 days ago - SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD) - PRNewsWire
- 6 weeks ago - Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 2 months ago - Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024 - GlobeNewsWire
- 3 months ago - Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins - GlobeNewsWire